
|Articles|November 1, 2012
Nonsurgical alternatives for treating lentigo maligna require caution
With a dearth of data regarding nonsurgical treatments for lentigo maligna (LM) and lentigo maligna melanoma (LMM), current American Academy of Dermatology guidelines advise caution regarding these therapies, said James M. Grichnik, M.D., Ph.D., at the academy's 70th annual meeting.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Kicking Off MOPD 2026 With Lawrence Schachner, MD
4
Sagimet and Ascletis Report Positive 52-Week Safety and Efficacy Data for Denifanstat in Acne
5











